Navigation Links
Signalife Receives Another $3.3 Million Sales Orders
Date:9/25/2007

LOS ANGELES, Sept. 25 /PRNewswire-FirstCall/ -- Earlier today, Signalife announced that it has received additional orders for the sale of $3.3 million (three million three hundred thousand dollars) of Fidelity 100 units as a continued result of new management's initial sales campaign. In the words of Signalife's President, Dr. Harmison, "That is $5.28 million of sales orders of our Fidelity 100 since I took over operational control of the Company, and -- as we fulfill our existing orders -- the Company will continue its efforts and expects to add additional sales to the system shortly."

About Signalife:

Signalife, Inc. is an award-winning life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements:

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities an Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Lucigen receives $750K grant to boost biofuel yields
3. Medical College receives $1.4M cancer grant
4. Wisconsin biotech firm receives $107K NIH grant
5. InvivoSciences receives NIH grant for heart technology
6. Medical College receives $11 million grant to study high blood pressure
7. Madison business receives $115,000 of new state biofuels funding
8. Superior receives funds for technical training
9. UWM receives state funding for plastics research
10. GEs Centricity EHR receives federal certification
11. WHIE receives state eHealth Initiative contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... The report "Cryocooler Market by ... (Technical Support, Product Repairs & Refurbishment, Preventive Maintenance, and ... 2022", published by MarketsandMarkets, the global market is expected ... a CAGR of 7.29% between 2016 and 2022. ... Figures spread through 159 Pages and in-depth TOC on ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... hold an open house for regional manufacturers at its Maple Grove, Minnesota technical ... Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 leading suppliers of tooling, ...
(Date:4/27/2016)... , April 27, 2016 ... NSK) (OTCPink: NSKQB) ( Frankfurt : ... ihre Pressemitteilung vom 13. August 2015 die Genehmigung ... Finanzen um zusätzliche 200.000.000 Einheiten auf 400.000.000 Einheiten ... zu bringen. Davon wurden 157.900.000 Einheiten mit dem ...
(Date:4/27/2016)... Manitoba (PRWEB) , ... April 27, 2016 , ... ... released for simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) ... better understanding disease and testing novel treatments in small animal subjects. Simultaneous PET/MRI ...
Breaking Biology Technology:
(Date:3/11/2016)... 2016 --> ... "Image Recognition Market by Technology (Pattern Recognition), by Component ... Deployment Type (On-Premises and Cloud), by Industry Vertical and ... MarketsandMarkets, the global market is expected to grow from ... by 2020, at a CAGR of 19.1%. ...
(Date:3/9/2016)... Fla. , March 9, 2016  Crossmatch ... authentication and enrollment solutions, today announced the addition ... ® Altus multi-factor authentication platform. New ... InfoSec managers to step-up security where it,s needed ... Washington, DC . --> ...
(Date:3/2/2016)... DUBLIN , March 2, 2016 /PRNewswire/ ... has announced the addition of the  "Global ... to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... sector to grow at a CAGR of ... http://www.researchandmarkets.com/research/wzwqtz/global_biometrics ) has announced the addition ...
Breaking Biology News(10 mins):